IMI Project PREFER – patient preferences in benefit-risk assessments – replay of the webinar now available

By Conny Berlin and Rachael L. DiSantostefano

In our 1-hour webinar on the 12 of July 2017 (4:30pm CET, 3:30pm GMT, 10:30am EST) we had a presentation by Conny Berlin who is the industry project leader of the public-private IMI PREFER project and by Rachael L. DiSantostefano member of IMI PREFER. They talked about:

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle: PREFER – an IMI Project

by Conny Berlin and Rachael L. DiSantostefano

The replay of the webinar including the Q&A is now available here:

Abstract:

The main objective of the IMI PREFER project is to strengthen patient-centric decision making throughout the life cycle of medicinal products by developing evidence-based recommendations to guide industry, Regulatory Authorities, HTA bodies, reimbursement agencies, academia, and health care professionals on how and when patient-preference studies should be performed and the results used to support and inform decision making.